SEC Form 4 · accession 0001209191-19-002819
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
LEE F Allen M.D. Ph.D.
Officer — Chief Medical Officer
Period of report
Jan 4, 2019
Accepted (ET)
Jan 8, 2019 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 4, 2019 | A | 9,070 | — | A | 12,570 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019.
- F2Each RSU represents a contingent right to receive one share of Issuer common stock.